GO:0002193 MAML1-RBP-Jkappa- ICN1 complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002193 describes the MAML1-RBP-Jkappa-ICN1 ternary complex, a nuclear transcriptional activation module that forms in response to Notch signaling.
• The complex consists of the Notch1 intracellular domain (ICN1), the DNA-binding factor RBP-Jkappa (CSL), and the coactivator Mastermind-like-1 (MAML1).
• Assembly of this complex is the committed step for canonical Notch target gene activation, including HES1, HEY1, and MYC.
• Deregulated formation of the MAML1-RBP-Jkappa-ICN1 complex is a hallmark of T-cell acute lymphoblastic leukemia (T-ALL) and is linked to gamma-secretase inhibitor resistance.
• The complex is regulated by multiple cofactors and post-translational inputs, including RUNX3, which can disrupt ICN1-RBP-Jkappa interactions.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential for dissecting the causal roles of each complex component in cancer and development.
Description
The MAML1-RBP-Jkappa-ICN1 complex (GO:0002193) is a nuclear protein assembly that serves as the central transcriptional switch for canonical Notch signaling. It forms when the Notch1 intracellular domain (ICN1) is released by gamma-secretase cleavage and translocates to the nucleus, where it binds the DNA-binding transcription factor RBP-Jkappa (also known as CSL) and recruits the transcriptional coactivator Mastermind-like-1 (MAML1). This ternary complex is required for activation of Notch target genes that control cell fate decisions, proliferation, and survival. Because the complex is a convergence point for oncogenic Notch signaling, it is a major focus in leukemia and solid tumor research. Understanding its composition, assembly, and regulation is therefore critical for developing targeted therapies and for interpreting CRISPR screens that probe Notch pathway dependencies.
MAML1-RBP-Jkappa- ICN1 complex At A Glance
| GO ID | GO:0002193 |
|---|---|
| GO term | MAML1-RBP-Jkappa- ICN1 complex |
| Ontology | cellular_component |
| Synonym | MAML1-CSL-ICN1; MAML1-CSL-Notch1 complex; MAML1-RBP-Jkappa-Notch1 complex |
| Major function | Transcriptional activation in response to Notch-mediated signaling |
| Components | ICN1 (Notch1 intracellular domain), RBP-Jkappa (CSL), MAML1 |
| Subcellular location | Nucleus |
| Pathological relevance | T-cell acute lymphoblastic leukemia, hepatocellular carcinoma, and other Notch-dependent cancers [4,5,7] |
What Is GO:0002193?
GO:0002193 is defined in QuickGO as a protein complex that consists of the intracellular domain of Notch1 (ICN1), the DNA-binding transcription factor RBP-Jkappa, and the transcriptional coactivator Mastermind-like-1 (MAML1); the complex is involved in transcriptional activation in response to Notch-mediated signaling. In other words, it is the active nuclear form of the Notch1 transcription factor, assembled on DNA to turn on target genes.
Why Is MAML1-RBP-Jkappa- ICN1 complex Important in Cell Biology?
The MAML1-RBP-Jkappa-ICN1 complex is the definitive readout of canonical Notch activation and a central node in cell-fate decisions, stem cell maintenance, and oncogenesis. Its assembly is required for the expression of HES and HEY family genes, which in turn regulate proliferation and differentiation. In T-cell acute lymphoblastic leukemia, gain-of-function NOTCH1 mutations drive constitutive complex formation and are associated with resistance to gamma-secretase inhibitors. The complex is also modulated by tumor suppressors such as RUNX3, which can disrupt ICN1-RBP-Jkappa binding and suppress Notch signaling in hepatocellular carcinoma. Consequently, the complex is a high-value target for mechanistic studies and therapeutic intervention [7,8].
• Serves as the committed step for canonical Notch target gene activation.
• Directly links Notch1 cleavage to transcriptional output in the nucleus.
• Is constitutively active in over 50% of T-ALL cases due to NOTCH1 mutations.
• Mediates resistance to gamma-secretase inhibitors in T-ALL.
• Is negatively regulated by RUNX3 in hepatocellular carcinoma.
• Controls stem cell self-renewal and differentiation across tissues.
• Represents a druggable protein-protein interface for Notch-directed therapies.
• Is a key node in CRISPR screens for Notch pathway dependencies.
• Its components are recurrently mutated in hematological malignancies [4,8].
• Provides a mechanistic explanation for context-dependent Notch functions in cancer.
What Happens During MAML1-RBP-Jkappa- ICN1 complex?
Notch1 cleavage and ICN1 nuclear translocation
In simple terms: Notch1 is cut, and its inside part moves to the nucleus.
Upon ligand binding, Notch1 undergoes sequential proteolytic cleavages, the last by gamma-secretase, releasing the intracellular domain ICN1. ICN1 then translocates to the nucleus, where it becomes available to assemble into the MAML1-RBP-Jkappa-ICN1 complex. This cleavage event is the rate-limiting step for canonical Notch signaling and is a target of gamma-secretase inhibitors.
DNA binding by RBP-Jkappa (CSL)
In simple terms: RBP-Jkappa sits on DNA and waits for ICN1.
RBP-Jkappa (also called CSL) is a sequence-specific DNA-binding protein that occupies promoter and enhancer elements of Notch target genes. In the absence of ICN1, RBP-Jkappa acts as a repressor by recruiting corepressor complexes. When ICN1 enters the nucleus, it binds RBP-Jkappa and displaces corepressors, converting RBP-Jkappa into an activator.
Recruitment of MAML1 and coactivators
In simple terms: MAML1 is the switch that turns on the gene.
The ICN1-RBP-Jkappa binary complex recruits MAML1 through a high-affinity interaction with the ankyrin repeat domain of ICN1. MAML1 then serves as a scaffold for additional coactivators, including p300/CBP, which acetylate histones and promote transcriptional elongation. Formation of the ternary MAML1-RBP-Jkappa-ICN1 complex is therefore the committed step for target gene activation.
Target gene activation and feedback
In simple terms: The complex turns on genes that can also shut it down.
The MAML1-RBP-Jkappa-ICN1 complex activates HES1, HEY1, and other canonical Notch targets. Some of these targets, such as HES1, feed back to repress Notch signaling, creating a self-limiting circuit. In cancer, this feedback is often disrupted, leading to sustained complex formation and oncogenic gene expression.
Regulation by RUNX3 and other cofactors
In simple terms: Other proteins can block the complex from forming.
RUNX3 directly interacts with ICN1 and suppresses Notch signaling in hepatocellular carcinoma cells, likely by competing with RBP-Jkappa or MAML1 for ICN1 binding. This illustrates that the MAML1-RBP-Jkappa-ICN1 complex is not constitutive but is subject to negative regulation by tumor suppressors. Additional cofactors and post-translational modifications further tune complex stability and activity.
Key Genes Involved in GO:0002193 MAML1-RBP-Jkappa- ICN1 complex
The following genes and proteins are core components, regulators, or downstream effectors of the MAML1-RBP-Jkappa-ICN1 complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NOTCH1 | Encodes the receptor whose intracellular domain (ICN1) is a core component of the complex | Most frequently mutated gene in T-ALL; target of gamma-secretase inhibitors [4,7] |
| RBPJ | Encodes RBP-Jkappa (CSL), the DNA-binding subunit of the complex | Central to Notch target gene specificity; knockout abolishes canonical Notch signaling |
| MAML1 | Encodes Mastermind-like-1, the transcriptional coactivator subunit | Required for complex assembly and target gene activation; potential therapeutic target |
| HES1 | Canonical Notch target gene activated by the complex | Readout of complex activity; feedback repressor of Notch signaling |
| HEY1 | Canonical Notch target gene activated by the complex | Biomarker of Notch activation in cancer and development |
| MYC | Notch target gene indirectly activated downstream of the complex | Drives proliferation in T-ALL; links complex to oncogenic metabolism |
| RUNX3 | Interacts with ICN1 and suppresses Notch signaling | Tumor suppressor that disrupts complex function in hepatocellular carcinoma |
| PSEN1 | Catalytic subunit of gamma-secretase that releases ICN1 | Target of gamma-secretase inhibitors; mutations affect complex formation |
| PSEN2 | Gamma-secretase subunit involved in Notch1 cleavage | Modulates ICN1 generation and complex assembly |
| NCOR1 | Corepressor that binds RBP-Jkappa in the absence of ICN1 | Maintains repression of Notch targets; displaced by ICN1 |
| NCOR2 | Corepressor complex component for RBP-Jkappa | Regulates basal repression of Notch target genes |
| EP300 | Histone acetyltransferase recruited by MAML1 | Coactivator that promotes transcription of complex targets |
| CREBBP | Histone acetyltransferase recruited by MAML1 | Coactivator that promotes transcription of complex targets |
| CDK8 | Kinase that can phosphorylate ICN1 and regulate complex activity | Modulates Notch-driven transcription in leukemia |
| FBXW7 | E3 ubiquitin ligase that targets ICN1 for degradation | Tumor suppressor; loss stabilizes ICN1 and increases complex formation |
| DTX1 | E3 ubiquitin ligase that regulates Notch1 trafficking and activation | Modulates ICN1 generation and complex assembly |
| LFNG | Glycosyltransferase that modifies Notch1 and affects ligand sensitivity | Tunes Notch activation and complex formation |
| RBPJL | RBP-Jkappa paralog that can substitute in some contexts | Context-dependent regulation of Notch target genes |
How Is MAML1-RBP-Jkappa- ICN1 complex Regulated?
The MAML1-RBP-Jkappa-ICN1 complex is regulated at multiple levels. ICN1 stability is controlled by ubiquitin ligases such as FBXW7, which targets ICN1 for proteasomal degradation and thereby limits complex formation. Gamma-secretase activity determines the amount of ICN1 available for nuclear import. RUNX3 can directly bind ICN1 and suppress Notch signaling, providing a tumor-suppressive brake on complex assembly in hepatocellular carcinoma. In T-ALL, mutations in NOTCH1 or FBXW7 lead to constitutive ICN1 accumulation and sustained complex activity, which can drive resistance to gamma-secretase inhibitors. Additionally, cofactors such as CDK8 and histone acetyltransferases modulate the transcriptional output of the assembled complex.
MAML1-RBP-Jkappa- ICN1 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NOTCH1 | T-cell acute lymphoblastic leukemia | NOTCH1 knockout and point-mutation knock-in in Jurkat cells |
| RUNX3 | Hepatocellular carcinoma | RUNX3 overexpression and knockout in HepG2 cells |
| FBXW7 | T-ALL and other cancers | FBXW7 knockout in T-ALL cell lines to stabilize ICN1 |
| MAML1 | Notch-driven cancers | MAML1 knockout and overexpression in HEK293T reporter cells |
| PSEN1 | T-ALL and Alzheimer's disease | PSEN1 knockout in patient-derived T-ALL cells |
T-cell acute lymphoblastic leukemia (T-ALL)
Deregulated NOTCH1 signaling is a hallmark of T-ALL, with activating mutations in NOTCH1 found in a majority of cases. These mutations promote constitutive formation of the MAML1-RBP-Jkappa-ICN1 complex, leading to sustained expression of oncogenic target genes such as MYC. Gamma-secretase inhibitors, which block ICN1 release, have shown efficacy but are limited by resistance mechanisms that often involve sustained complex activity. The complex is therefore a central therapeutic node in T-ALL [4,7].
Hepatocellular carcinoma (HCC)
In hepatocellular carcinoma cells, RUNX3 directly interacts with ICN1 and suppresses Notch signaling, likely by disrupting the MAML1-RBP-Jkappa-ICN1 complex. Loss of RUNX3 function may therefore unleash Notch-driven transcription and contribute to tumor progression. This highlights the complex as a context-dependent oncogenic driver in liver cancer.
Other Notch-dependent malignancies
The MAML1-RBP-Jkappa-ICN1 complex is implicated in a broad range of cancers where Notch signaling is deregulated, including breast, lung, and pancreatic cancers. In these contexts, the complex can act as either an oncogene or a tumor suppressor depending on the tissue. Understanding its assembly and regulation is essential for predicting responses to Notch-targeted therapies.
From MAML1-RBP-Jkappa- ICN1 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MAML1 abolish Notch target gene activation? | MAML1 knockout in HEK293T or Jurkat cells |
| Does a specific NOTCH1 mutation drive constitutive complex formation? | NOTCH1 point-mutation knock-in in T-ALL cell lines |
| Can a tagged ICN1 be used to purify the complex? | Tagged knock-in of NOTCH1 (e.g., FLAG-ICN1) in HEK293T cells |
| Does RUNX3 overexpression disrupt the complex? | RUNX3 overexpression in hepatocellular carcinoma cells |
| Does FBXW7 loss stabilize ICN1 and increase complex activity? | FBXW7 knockout in T-ALL cell lines |
| Can the complex be visualized in live cells? | Knock-in of fluorescent protein tags at NOTCH1 or MAML1 loci |
How to Study the MAML1-RBP-Jkappa- ICN1 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ChIP-seq | Genomic binding sites of ICN1, RBP-Jkappa, or MAML1 | Mapping Notch target enhancers |
| Co-IP / mass spectrometry | Protein-protein interactions and complex composition | Identifying novel cofactors |
| Luciferase reporter assay | Transcriptional activity of the complex | Screening for Notch inhibitors |
| RNA-seq | Changes in Notch target gene expression | Assessing complex loss-of-function |
| CRISPR knockout screen | Genes required for complex function | Identifying resistance mechanisms |
| Proximity ligation assay | In situ detection of ICN1-RBP-Jkappa interaction | Visualizing complex assembly in cells |
| Western blot | Protein levels of ICN1, RBP-Jkappa, MAML1 | Validating knockout or overexpression |
| Flow cytometry | Notch-dependent reporter activity | Sorting cells with active complex |
Chromatin immunoprecipitation (ChIP)
ChIP with antibodies against ICN1, RBP-Jkappa, or MAML1 can map the genomic binding sites of the MAML1-RBP-Jkappa-ICN1 complex. This method reveals which promoters and enhancers are occupied by the complex and how binding changes upon Notch activation or inhibition.
Co-immunoprecipitation and mass spectrometry
Co-immunoprecipitation of ICN1 or MAML1 followed by mass spectrometry identifies the composition and stoichiometry of the MAML1-RBP-Jkappa-ICN1 complex. This approach can also detect post-translational modifications and additional cofactors that associate with the complex.
Transcriptional reporter assays
Luciferase reporters driven by Notch-responsive elements (e.g., HES1 promoter) are used to measure the transcriptional activity of the MAML1-RBP-Jkappa-ICN1 complex. These assays are suitable for high-throughput screening of inhibitors or genetic perturbations.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate the assembly or activity of the MAML1-RBP-Jkappa-ICN1 complex. Such screens have revealed context-specific dependencies and resistance mechanisms in T-ALL.
How CRISPR Can Be Used to Study GO:0002193 MAML1-RBP-Jkappa- ICN1 complex
Knockout
CRISPR knockout of NOTCH1, RBPJ, or MAML1 abolishes formation of the MAML1-RBP-Jkappa-ICN1 complex and blocks Notch target gene activation. These models are essential for confirming the requirement of each subunit in canonical Notch signaling. Knockout of negative regulators such as FBXW7 stabilizes ICN1 and enhances complex activity.
Point Mutation
Point mutations in NOTCH1, such as those found in T-ALL, can be introduced by CRISPR to model constitutive complex formation. These models help dissect how specific mutations affect ICN1 stability, nuclear localization, and interaction with RBP-Jkappa and MAML1. They are also useful for testing targeted therapies.
Knock-in
Knock-in of epitope or fluorescent tags at the NOTCH1 or MAML1 loci enables purification and live-cell imaging of the MAML1-RBP-Jkappa-ICN1 complex. Tagged knock-in models preserve endogenous regulation and are ideal for proteomic and single-molecule studies.
Overexpression
Overexpression of ICN1, RBP-Jkappa, or MAML1 via CRISPR activation or lentiviral delivery can drive constitutive complex formation and activate Notch targets. These models are used to study oncogenic potential and to screen for inhibitors of the complex.
How EDITGENE Supports MAML1-RBP-Jkappa- ICN1 complex Research
Researchers studying MAML1-RBP-Jkappa-ICN1 complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, transcriptional output, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based cell model services to enable these investigations with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for MAML1-RBP-Jkappa- ICN1 complex research.
Frequently Asked Questions About MAML1-RBP-Jkappa- ICN1 complex
What is the MAML1-RBP-Jkappa-ICN1 complex?
It is a nuclear protein complex consisting of the Notch1 intracellular domain (ICN1), the DNA-binding factor RBP-Jkappa, and the coactivator MAML1, which activates Notch target genes.
What genes are involved in the MAML1-RBP-Jkappa-ICN1 complex?
The core genes are NOTCH1, RBPJ, and MAML1; additional regulators include FBXW7, RUNX3, and PSEN1 [4,5].
What is GO:0002193?
GO:0002193 is the Gene Ontology identifier for the MAML1-RBP-Jkappa-ICN1 complex, a cellular component involved in Notch-mediated transcriptional activation.
How is the MAML1-RBP-Jkappa-ICN1 complex assembled?
It assembles when gamma-secretase releases ICN1, which enters the nucleus, binds RBP-Jkappa on DNA, and recruits MAML1.
What diseases are associated with the MAML1-RBP-Jkappa-ICN1 complex?
It is strongly linked to T-cell acute lymphoblastic leukemia and hepatocellular carcinoma, among other Notch-dependent cancers [4,5,7].
How can I study the MAML1-RBP-Jkappa-ICN1 complex in the lab?
Common methods include ChIP-seq, co-immunoprecipitation, luciferase reporter assays, and CRISPR knockout models [4,8].
What is the role of MAML1 in Notch signaling?
MAML1 is the transcriptional coactivator that is recruited to the ICN1-RBP-Jkappa complex and is required for target gene activation.
Can CRISPR be used to model Notch-driven cancers?
Yes, CRISPR knockout, point mutation knock-in, and overexpression models are widely used to study Notch-driven cancers such as T-ALL [4,7].
What is the difference between ICN1 and Notch1?
Notch1 is the full-length receptor; ICN1 is the intracellular domain released by cleavage that enters the nucleus to form the complex.
How does RUNX3 affect the MAML1-RBP-Jkappa-ICN1 complex?
RUNX3 directly interacts with ICN1 and suppresses Notch signaling, likely by disrupting complex formation in hepatocellular carcinoma cells.
Conclusion
The MAML1-RBP-Jkappa-ICN1 complex (GO:0002193) is the central transcriptional effector of canonical Notch signaling and a critical node in development and cancer. Its assembly is tightly regulated by proteolysis, cofactor availability, and tumor suppressors such as RUNX3. Dysregulation of the complex drives T-ALL and other malignancies, making it a prime target for therapeutic intervention. CRISPR-based cell models, combined with genomic and proteomic methods, provide powerful tools to dissect its function and identify new treatments.
References
- 4. Aster JC. 2005. Deregulated NOTCH signaling in acute T-cell lymphoblastic leukemia/lymphoma: new insights, questions, and opportunities.. Int J Hematol 82(4):295-301 PMID: 16298817
- 5. Gao J et al.. 2010. RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells.. Exp Cell Res 316(2):149-57 PMID: 19800882
- 7. Hales EC et al.. 2014. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.. Cell Signal 26(1):149-61 PMID: 24140475
- 8. Robles-Valero J et al.. 2017. A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia.. Cancer Cell 32(5):608-623.e9 PMID: 29136506
